David Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
David Wang has a total of 515 co-authors. Here are the top co-authors by number of shared publications:
- Yongjun Wang
Department of Neurology, Beijing Tiantan Hospital affiliated to Capital Medical University, Beijing, China
13 shared publications - Bo Hu
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
8 shared publications - Liping Liu
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
7 shared publications Candong Hong
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
4 shared publicationsJiang Chang
School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 shared publications- Jing Jing
China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
4 shared publications
Latest Publications
- Open Access
- 31 July 2026
- Published by BMJ in Stroke and Vascular Neurology
China Stroke Statistics 2023: a report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, National Collaborating Centre for Neurological Disorders Prevention, the Chinese Stroke Association and Institute for Global Neuroscience and Stroke Collaborations
Background: Stroke remains a leading cause of mortality and adult disability in China, imposing a substantial disease and socioeconomic burden on society, yet nationally representative epidemiological and real-world inpatient care data remain insufficient. Methods: This study integrated data from the Global Burden of Disease 2023, the Hospital Quality Monitoring System (7536 hospitals) in 2023, and the 2021 National Mortality Surveillance System to systematically assess the epidemiology, disease burden, inpatient care patterns, clinical outcomes and average costs of stroke per hospitalisation in China. Results: In 2023, China reported 4.23 million incident cases, 26.68 million prevalent cases and 2.05 million deaths from stroke. Despite declining age-standardised incidence and mortality, ischaemic stroke (IS) prevalence continued to increase, while haemorrhagic stroke remains the principal contributor to disability-adjusted life years. Real-world inpatient data showed that males and older adults accounted for higher proportions of stroke admissions. Stroke admissions were predominantly concentrated in tertiary public hospitals with marked regional variation. Haemorrhagic stroke has substantially higher in-hospital mortality (intracerebral haemorrhage, ICH: 4.23%; subarachnoid haemorrhage, SAH: 4.08% vs IS: 0.49%) and adverse discharge outcomes than IS. Tertiary hospitals exhibited higher mortality (1.19% vs 0.62%) but lower 0–31-day readmission rates (1.19% vs 1.63%) than secondary hospitals, whereas private hospitals showed longer hospital stays (10.54 vs 9.86 days) and higher readmission rates (1.88% vs 1.34%) than public institutions. The mean hospitalisation cost was RMB13 927 (US$1900) per admission, with substantially higher costs for SAH and ICH than for IS. Conclusions: This nationwide analysis provides comprehensive real-world evidence on the epidemiological burden, inpatient care patterns, clinical outcomes and hospitalisation costs of stroke in China, identifying substantial national, regional and hospital-level variations that may inform future research and quality improvement efforts.
- 31 July 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessChina Stroke Statistics 2023: a report from the National Center for Healthcare Quality Management in Neurological Diseases, China National Clinical Research Center for Neurological Diseases, National Collaborating Centre for Neurological Disorders Prevention, the Chinese Stroke Association and Institute for Global Neuroscience and Stroke Collaborations
Background: Stroke remains a leading cause of mortality and adult disability in China, imposing a substantial disease and socioeconomic burden on society, yet nationally representative epidemiological and real-world inpatient care data remain insufficient. Methods: This study integrated data from the Global Burden of Disease 2023, the Hospital Quality Monitoring System (7536 hospitals) in 2023, and the 2021 National Mortality Surveillance System to systematically assess the epidemiology, disease burden, inpatient care patterns, clinical outcomes and average costs of stroke per hospitalisation in China. Results: In 2023, China reported 4.23 million incident cases, 26.68 million prevalent cases and 2.05 million deaths from stroke. Despite declining age-standardised incidence and mortality, ischaemic stroke (IS) prevalence continued to increase, while haemorrhagic stroke remains the principal contributor to disability-adjusted life years. Real-world inpatient data showed that males and older adults accounted for higher proportions of stroke admissions. Stroke admissions were predominantly concentrated in tertiary public hospitals with marked regional variation. Haemorrhagic stroke has substantially higher in-hospital mortality (intracerebral haemorrhage, ICH: 4.23%; subarachnoid haemorrhage, SAH: 4.08% vs IS: 0.49%) and adverse discharge outcomes than IS. Tertiary hospitals exhibited higher mortality (1.19% vs 0.62%) but lower 0–31-day readmission rates (1.19% vs 1.63%) than secondary hospitals, whereas private hospitals showed longer hospital stays (10.54 vs 9.86 days) and higher readmission rates (1.88% vs 1.34%) than public institutions. The mean hospitalisation cost was RMB13 927 (US$1900) per admission, with substantially higher costs for SAH and ICH than for IS. Conclusions: This nationwide analysis provides comprehensive real-world evidence on the epidemiological burden, inpatient care patterns, clinical outcomes and hospitalisation costs of stroke in China, identifying substantial national, regional and hospital-level variations that may inform future research and quality improvement efforts.
- Open Access
- 15 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Endovascular treatment for symptomatic intracranial artery stenosis: current strategies and future challenges
Over the past two decades, substantial progress has been made in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis (sICAS). In this study, we performed a comprehensive review focusing on patient selection criteria, advanced imaging modalities for lesion characterisation, evolving endovascular therapeutic approaches, the innovation of next-generation neurointerventional devices, and the evidence-based recommendations outlined in clinical guidelines and expert consensus statements for the treatment of sICAS.
- 15 April 2026
- Published by BMJ in Stroke and Vascular Neurology
Open AccessEndovascular treatment for symptomatic intracranial artery stenosis: current strategies and future challenges
Over the past two decades, substantial progress has been made in the endovascular treatment of symptomatic intracranial atherosclerotic stenosis (sICAS). In this study, we performed a comprehensive review focusing on patient selection criteria, advanced imaging modalities for lesion characterisation, evolving endovascular therapeutic approaches, the innovation of next-generation neurointerventional devices, and the evidence-based recommendations outlined in clinical guidelines and expert consensus statements for the treatment of sICAS.
- Open Access
- 2 May 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (1) , 1-5
Thrombolytic agents, more options, more challenges
Acute ischaemic stroke (AIS) is a leading cause of disability and mortality worldwide. Intravenous thrombolytic therapy is the cornerstone treatments, aiming to restore blood flow in the occluded cerebral vessels. Alteplase has been the standard thrombolytic agent since 1995. However, the exploration of other available thrombolytic agents such as tenecteplase (TNK), prourokinase and reteplase for easier administration, more effective and safer alternatives has led to the development of new agents. 1 Dozens of trials were performed to compare those to conventional alteplase, especially among specific subgroup patients. We would like to illustrate the pearls and pitfalls in AIS care. A better understanding of these new alternative agents will assist clinicians to adhere to the guidelines and yet know the pros and cons of potential options.
- 2 May 2025
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 11 (1) , 1-5
Open AccessThrombolytic agents, more options, more challenges
Acute ischaemic stroke (AIS) is a leading cause of disability and mortality worldwide. Intravenous thrombolytic therapy is the cornerstone treatments, aiming to restore blood flow in the occluded cerebral vessels. Alteplase has been the standard thrombolytic agent since 1995. However, the exploration of other available thrombolytic agents such as tenecteplase (TNK), prourokinase and reteplase for easier administration, more effective and safer alternatives has led to the development of new agents. 1 Dozens of trials were performed to compare those to conventional alteplase, especially among specific subgroup patients. We would like to illustrate the pearls and pitfalls in AIS care. A better understanding of these new alternative agents will assist clinicians to adhere to the guidelines and yet know the pros and cons of potential options.
- Open Access
- 12 December 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 741-745
Chinese Stroke Association guidelines on emergency stroke unit
Organised stroke care has become a keystone in delivering efficient and effective treatment to patients with stroke with improved outcomes. Delivering timely acute reperfusion therapy to those with acute ischaemic strokes is key to good recovery. Emergency stroke unit (ESU) is a novel organised stroke care system developed in China. It centralises all necessary procedures for the diagnosis and treatment of acute stroke into one unit that can perform clinical assessment, imaging examination and acute treatments. In ESU, artificial intelligence algorithms are used to aid in reading brain images and making clinical decisions. Therefore, ESU can significantly enhance the efficiency of emergent stroke care. In this guideline, we aim to clarify the concept, construction standards and personnel requirements of an ESU, standardise ESU-based acute stroke triage and treatment workflow, establish metrics of quality control, facilitate the construction and promotion of ESU and continue the improvement of the quality of stroke care.
- 12 December 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 741-745
Open AccessChinese Stroke Association guidelines on emergency stroke unit
Organised stroke care has become a keystone in delivering efficient and effective treatment to patients with stroke with improved outcomes. Delivering timely acute reperfusion therapy to those with acute ischaemic strokes is key to good recovery. Emergency stroke unit (ESU) is a novel organised stroke care system developed in China. It centralises all necessary procedures for the diagnosis and treatment of acute stroke into one unit that can perform clinical assessment, imaging examination and acute treatments. In ESU, artificial intelligence algorithms are used to aid in reading brain images and making clinical decisions. Therefore, ESU can significantly enhance the efficiency of emergent stroke care. In this guideline, we aim to clarify the concept, construction standards and personnel requirements of an ESU, standardise ESU-based acute stroke triage and treatment workflow, establish metrics of quality control, facilitate the construction and promotion of ESU and continue the improvement of the quality of stroke care.
- Open Access
- 28 November 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 415-417
Improved functional outcome for stroke patients with low ASPECTS score large core infarctions: 1-year follow-up of three randomised trials
Several randomised controlled trials (RCTs)1–5 have established 3-month efficacy and safety of endovascular thrombectomy (EVT) in treating patients with acute ischaemic stroke (AIS) with a large infarct core and low Alberta Stroke Program Early Computed Tomographic Scores (ASPECTS), between 3 and 5. Despite EVT, these patients have a higher rate of mortality and unfavourable outcomes at 3 months, delayed recovery or secondary deterioration.6 The long-term outcomes for these patients remain largely uncertain and unexplored.
- 28 November 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 415-417
Open AccessImproved functional outcome for stroke patients with low ASPECTS score large core infarctions: 1-year follow-up of three randomised trials
Several randomised controlled trials (RCTs)1–5 have established 3-month efficacy and safety of endovascular thrombectomy (EVT) in treating patients with acute ischaemic stroke (AIS) with a large infarct core and low Alberta Stroke Program Early Computed Tomographic Scores (ASPECTS), between 3 and 5. Despite EVT, these patients have a higher rate of mortality and unfavourable outcomes at 3 months, delayed recovery or secondary deterioration.6 The long-term outcomes for these patients remain largely uncertain and unexplored.
- Open Access
- 20 November 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 472-480
0.23-Tesla MRI to differentiate between ischaemic and haemorrhagic strokes within 24 hours of onset: a combined experimental–clinical study
Background and purpose: The low-field MRI is a promising tool to accurately diagnose strokes. We here report our study on the accuracy of a 0.23-Tesla (0.23-T) MRI using the haematoma enhanced inversion recovery (HEIR) sequence to detect acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH) within 24 hours of symptom onset. Methods: A novel HEIR sequence based on fluid-attenuated inversion recovery T1-weighted, with a scanning time of 1 min and 17 s, was developed using an ICH and AIS pig model on a 0.23-T MRI. Images of the pig model were obtained hourly for 24 hours in order to monitor value changes on T1/T2 and verify the differential diagnosis of AIS and ICH. Then, 30 patients with AIS and 30 patients with ICH with confirmed diagnoses by 3T-MRI/CT were included. Diagnostic criteria on a 0.23-T MRI for ICH was the hyperintensity signal on both the diffusion-weighted imaging (DWI) and HEIR sequence, while for AIS was the hyperintensity on DWI and isointensity on the HEIR sequence. Two blinded raters independently assessed the images obtained by the 0.23-T MRI for the presence of ICH/AIS. Results: In the pig model, setting the inversion time to 800 ms enabled clear differentiation of ICH from brain parenchymal tissue and AIS. In real patients, a correct 0.23-T MRI diagnosis of either an AIS or ICH was made in all 60 patients within 24 hours of symptom onset (100% overall accuracy). No adverse events occurred. Conclusions: The 0.23-T MRI may have the potential to differentiate cerebral haemorrhage from cerebral infarction with both speed and accuracy, making brain MRI scans easier, faster and cheaper. It might be possible to improve the screening imaging process for strokes in the emergency room. Further multicentre studies are needed to validate our findings.
- 20 November 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 472-480
Open Access0.23-Tesla MRI to differentiate between ischaemic and haemorrhagic strokes within 24 hours of onset: a combined experimental–clinical study
Background and purpose: The low-field MRI is a promising tool to accurately diagnose strokes. We here report our study on the accuracy of a 0.23-Tesla (0.23-T) MRI using the haematoma enhanced inversion recovery (HEIR) sequence to detect acute ischaemic stroke (AIS) and intracerebral haemorrhage (ICH) within 24 hours of symptom onset. Methods: A novel HEIR sequence based on fluid-attenuated inversion recovery T1-weighted, with a scanning time of 1 min and 17 s, was developed using an ICH and AIS pig model on a 0.23-T MRI. Images of the pig model were obtained hourly for 24 hours in order to monitor value changes on T1/T2 and verify the differential diagnosis of AIS and ICH. Then, 30 patients with AIS and 30 patients with ICH with confirmed diagnoses by 3T-MRI/CT were included. Diagnostic criteria on a 0.23-T MRI for ICH was the hyperintensity signal on both the diffusion-weighted imaging (DWI) and HEIR sequence, while for AIS was the hyperintensity on DWI and isointensity on the HEIR sequence. Two blinded raters independently assessed the images obtained by the 0.23-T MRI for the presence of ICH/AIS. Results: In the pig model, setting the inversion time to 800 ms enabled clear differentiation of ICH from brain parenchymal tissue and AIS. In real patients, a correct 0.23-T MRI diagnosis of either an AIS or ICH was made in all 60 patients within 24 hours of symptom onset (100% overall accuracy). No adverse events occurred. Conclusions: The 0.23-T MRI may have the potential to differentiate cerebral haemorrhage from cerebral infarction with both speed and accuracy, making brain MRI scans easier, faster and cheaper. It might be possible to improve the screening imaging process for strokes in the emergency room. Further multicentre studies are needed to validate our findings.
- Open Access
- 3 August 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 418-421
Should patients with minor strokes be given thrombolytics?
Mild stroke symptoms are cited as the reason for not using tissue-type plasminogen activator in 29–43% of time-eligible patients. Previous studies suggested that not all of these patients had a good recovery or even survival to hospital discharge. Since then, stroke guidelines worldwide recommended thrombolysis in minor but disabling strokes. Dual antiplatelet treatment with aspirin and clopidogrel was more effective than aspirin alone for reducing subsequent events in patients with minor stroke if started within 24 hours of onset in both CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke) trials. Recently, both PRISMS (The Potential of rtPA for Ischemic Strokes With Mild Symptoms) trial and TEMPO-2 (Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion) trial showed that treatment with thrombolysis versus antiplatelet did not increase the likelihood of favourable functional outcome at 90 days among patients with minor non-disabling acute ischaemic strokes. Therefore, a narrative review on thrombolysis for patients with minor strokes from published studies may help practicing clinicians.
- 3 August 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 10 (4) , 418-421
Open AccessShould patients with minor strokes be given thrombolytics?
Mild stroke symptoms are cited as the reason for not using tissue-type plasminogen activator in 29–43% of time-eligible patients. Previous studies suggested that not all of these patients had a good recovery or even survival to hospital discharge. Since then, stroke guidelines worldwide recommended thrombolysis in minor but disabling strokes. Dual antiplatelet treatment with aspirin and clopidogrel was more effective than aspirin alone for reducing subsequent events in patients with minor stroke if started within 24 hours of onset in both CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) and POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke) trials. Recently, both PRISMS (The Potential of rtPA for Ischemic Strokes With Mild Symptoms) trial and TEMPO-2 (Tenecteplase Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion) trial showed that treatment with thrombolysis versus antiplatelet did not increase the likelihood of favourable functional outcome at 90 days among patients with minor non-disabling acute ischaemic strokes. Therefore, a narrative review on thrombolysis for patients with minor strokes from published studies may help practicing clinicians.
- Open Access
- 28 March 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 693-698
Assessment of Perfusion Volumes by a New Automated Software for Computed Tomography Perfusion
Introduction To compare the perfusion volumes assessed by a new automated CT perfusion (CTP) software iStroke with the circular singular value decomposition software RAPID and determine its predictive value for functional outcome in patients with acute ischaemic stroke (AIS) who underwent endovascular treatment (EVT). Methods Data on patients with AIS were collected from four hospitals in China. All patients received CTP followed by EVT with complete recanalisation within 24 hours of symptom onset. We evaluated the agreement of CTP measures between the two softwares by Spearman’s rank correlation tests and kappa tests. Bland-Altman plots were used to evaluate the agreement of infarct core volume (ICV) on CTP and ground truth on diffusion-weighted imaging (DWI). Logistic regression models were used to test the association between ICV on these two softwares and functional outcomes. Results Among 326 patients, 228 had DWI examinations and 40 of them had infarct volume >70 mL. In all patients, the infarct core and hypoperfusion volumes on iStroke had a strong correlation with those on RAPID (ρ=0.68 and 0.66, respectively). The agreement of large infarct core (volume >70 mL) was substantial (kappa=0.73, pConclusion The automatic CTP software iStroke is a reliable tool for assessing infarct core and mismatch volumes, making it clinically useful for selecting patients with AIS for acute reperfusion therapy in the extended time window.
- 28 March 2024
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (6) , 693-698
Open AccessAssessment of Perfusion Volumes by a New Automated Software for Computed Tomography Perfusion
Introduction To compare the perfusion volumes assessed by a new automated CT perfusion (CTP) software iStroke with the circular singular value decomposition software RAPID and determine its predictive value for functional outcome in patients with acute ischaemic stroke (AIS) who underwent endovascular treatment (EVT). Methods Data on patients with AIS were collected from four hospitals in China. All patients received CTP followed by EVT with complete recanalisation within 24 hours of symptom onset. We evaluated the agreement of CTP measures between the two softwares by Spearman’s rank correlation tests and kappa tests. Bland-Altman plots were used to evaluate the agreement of infarct core volume (ICV) on CTP and ground truth on diffusion-weighted imaging (DWI). Logistic regression models were used to test the association between ICV on these two softwares and functional outcomes. Results Among 326 patients, 228 had DWI examinations and 40 of them had infarct volume >70 mL. In all patients, the infarct core and hypoperfusion volumes on iStroke had a strong correlation with those on RAPID (ρ=0.68 and 0.66, respectively). The agreement of large infarct core (volume >70 mL) was substantial (kappa=0.73, pConclusion The automatic CTP software iStroke is a reliable tool for assessing infarct core and mismatch volumes, making it clinically useful for selecting patients with AIS for acute reperfusion therapy in the extended time window.
- Top Cited PapersOpen Access
- 29 December 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 8 (6) , e3
Chinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update
Background: China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases. Methods: We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee. Results: This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management. Conclusions: This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.
- 29 December 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 8 (6) , e3
Top Cited PapersOpen AccessChinese Stroke Association guidelines for clinical management of ischaemic cerebrovascular diseases: executive summary and 2023 update
Background: China is one of the countries with the highest burden of stroke. Implementing multidimensional management guidelines will help clinicians practise evidence-based care, improve patient outcomes and alleviate societal burdens. This update of the 2019 edition will provide the latest comprehensive recommendations for the diagnosis and treatment of ischaemic cerebrovascular diseases. Methods: We conducted a comprehensive search on MEDLINE (via PubMed) up to 31 August 2023. The writing team established the recommendations through multiple rounds of online and offline discussions. Each recommendation was graded using the evidence grading algorithm developed by the Chinese Stroke Association (CSA). The draft was reviewed and finalised by the CSA Stroke Guidelines Writing Committee. Results: This update included revisions of 15 existing recommendations and 136 new recommendations in the following areas of stroke care: emergency assessment and diagnosis of ischaemic cerebrovascular disease, acute-phase reperfusion therapy, evaluation of underlying mechanisms, antithrombotic therapy, prevention and treatment of complications, and risk factor management. Conclusions: This guideline updated the recommendations for the clinical management of ischaemic cerebrovascular disease from 2019.
- Open Access
- 21 December 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (5) , 461-463
When treating acute ischaemic stroke of LVO type, time window prevails over tissue window
- 21 December 2023
- Published by BMJ in Stroke and Vascular Neurology
- Vol. 9 (5) , 461-463
Open AccessWhen treating acute ischaemic stroke of LVO type, time window prevails over tissue window